Source link : https://www.newshealth.biz/health-news/fda-approves-benralizumab-for-egpa-vasculitis-indication/
The US Food and Drug Administration (FDA) has approved benralizumab (Fasenra) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome. The drug is the second approved biologic for the treatment of EGPA. The first, mepolizumab (Nucala), was approved in 2017. “This disease has a devastating impact on […]
Author : News Health
Publish date : 2024-09-18 19:38:13
Copyright for syndicated content belongs to the linked Source.
Categories